2-(Bromomethyl)-1,2,3,4-tetrahydronaphthalene | 77508-59-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-(Bromomethyl)-1,2,3,4-tetrahydronaphthalene
• 英文别名: 2-bromomethyl-1,2,3,4-tetrahydro-2-naphthalene
• CAS: 77508-59-9
• 化学式: C₁₁H₁₃Br
• mdl: MFCD09868528
• 分子量: 225.128
• InChiKey: MUGPULGJDGEABF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-(Bromomethyl)-1,2,3,4-tetrahydronaphthalene 在 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 苯 为溶剂， 反应 16.0h， 以57%的产率得到2-甲基-1,2,3,4-四氢萘
  参考文献：
  名称：

  Beckwith, Athelstan L. J.; Gerba, Sendaba, Australian Journal of Chemistry, 1992, vol. 45, # 1, p. 289 - 308

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2,3,4-四氢-2-萘甲酸甲酯 在 六甲基磷酰三胺 、 lithium aluminium tetrahydride 、 lithium bromide 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 8.25h， 生成 2-(Bromomethyl)-1,2,3,4-tetrahydronaphthalene
  参考文献：
  名称：

  Beckwith, Athelstan L. J.; Gerba, Sendaba, Australian Journal of Chemistry, 1992, vol. 45, # 1, p. 289 - 308

  摘要：

  DOI：

文献信息

• Aromatic amine derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05508306A1

  公开（公告）日：1996-04-16

  This invention relates to novel aromatic amine compounds having the structure: ##STR1## where each W, Z.sup.1 and Z.sup.2 is independently H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, OH, F, Cl, Br, I, NO.sub.2, CN, SO.sub.2 NHR.sup.3, NR.sup.4.sub.2, CONR.sup.3.sub.2, COR.sup.5 ; where each R.sup.1 and R.sup.2 is independently H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where each X and Y is independently CH.sub.2, NR.sup.4, S, S.dbd.O, SO.sub.2 ; where n is 0, 1 or 2; where each p and q is independently 1 or 2; where R.sup.3 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where R.sup.4 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or COR.sup.3 ; and where R.sup.5 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl, C.sub.1 -C.sub.6 straight or branched chain alkoxy or OH. In addition the invention includes using such compounds for the treatment of benign prostatic hyperplasia, lowering intraocular pressure and inhibiting cholesterol synthesis.

  这项发明涉及具有以下结构的新型芳香胺化合物：其中每个W，Z.sup.1和Z.sup.2独立地为H，C.sub.1 -C.sub.6烷基，C.sub.1 -C.sub.6烷氧基，OH，F，Cl，Br，I，NO.sub.2，CN，SO.sub.2NHR.sup.3，NR.sup.4.sub.2，CONR.sup.3.sub.2，COR.sup.5；其中每个R.sup.1和R.sup.2独立地为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中每个X和Y独立地为CH.sub.2，NR.sup.4，S，S.dbd.O，SO.sub.2；其中n为0、1或2；其中每个p和q独立地为1或2；其中R.sup.3为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中R.sup.4为H，C.sub.1 -C.sub.6直链或支链烷基或COR.sup.3；其中R.sup.5为H，C.sub.1 -C.sub.6直链或支链烷基或苯基，C.sub.1 -C.sub.6直链或支链烷氧基或OH。此外，该发明还包括使用这些化合物治疗良性前列腺增生、降低眼内压和抑制胆固醇合成。
• Use of .alpha.-1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05578611A1

  公开（公告）日：1996-11-26

  The subject invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, a human histamine H.sub.1 receptor and .alpha..sub.2 adrenergic receptor. The subject invention also provides a method of inhibiting contraction of prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of such compound.

  该发明提供了一种治疗良性前列腺增生的方法，包括向受试者施用一种与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比化合物与人类α1A肾上腺素受体、人类α1B肾上腺素受体、人类组胺H1受体和α2肾上腺素受体结合的亲和力高出十倍以上。该发明还提供了一种抑制前列腺组织收缩的方法，包括用该化合物接触前列腺组织，使其受到有效的抑制收缩作用的量。
• Use of .alpha..sub.1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05403847A1

  公开（公告）日：1995-04-04

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生的方法，包括向患者投与一种与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低出十倍以上。提供符合这些标准的化合物。
• .alpha..sub.1C specific compounds to treat benign prostatic hyperplasia
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05990128A1

  公开（公告）日：1999-11-23

  This invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor; and (b) binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than 100-fold lower than the binding affinity with which the .alpha..sub.1C antagonist binds to such .alpha..sub.1C adrenergic receptor. The invention further provides a method of inhibiting contraction of a prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor; and (b) binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than 100-fold lower than the binding affinity with which the .alpha..sub.1C antagonist binds to such .alpha..sub.1C adrenergic receptor.

  该发明提供了一种治疗良性前列腺增生的方法，该方法包括向受试者施用治疗有效量的α1C受体拮抗剂，该拮抗剂（a）与人类α1C肾上腺素受体结合的亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组织胺H1受体结合的亲和力高100倍以上；以及（b）与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低100倍以上。该发明还提供了一种抑制前列腺组织收缩的方法，该方法包括将前列腺组织与有效的抑制收缩量的α1C受体拮抗剂接触，该拮抗剂（a）与人类α1C肾上腺素受体结合的亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组织胺H1受体结合的亲和力高100倍以上；以及（b）与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低100倍以上。
• Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06015819A1

  公开（公告）日：2000-01-18

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生的方法，包括向受试者投予与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低出十倍以上。提供符合这些标准的化合物。